{"id":"https://openalex.org/W2461621821","doi":"https://doi.org/10.1158/1538-7445.am2015-2689","title":"Abstract 2689: Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study","display_name":"Abstract 2689: Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study","publication_year":2015,"publication_date":"2015-08-01","ids":{"openalex":"https://openalex.org/W2461621821","doi":"https://doi.org/10.1158/1538-7445.am2015-2689","mag":"2461621821"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2015-2689","doi":"https://doi.org/10.1158/1538-7445.am2015-2689","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2015-2689","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086626483","display_name":"Shumei Kato","orcid":"https://orcid.org/0000-0003-1193-1815","observed_orcids":["https://orcid.org/0000-0003-1193-1815"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shumei Kato","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005436649","display_name":"Aung Naing","orcid":"https://orcid.org/0000-0002-4803-8513","observed_orcids":["https://orcid.org/0000-0002-4803-8513"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aung Naing","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069777765","display_name":"Gerald Steven Falchook","orcid":"https://orcid.org/0000-0001-9165-2191","observed_orcids":["https://orcid.org/0000-0001-9165-2191"]},"institutions":[{"id":"https://openalex.org/I4210120438","display_name":"HealthONE","ror":"https://ror.org/032y5sx52","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210120438"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gerald Falchook","raw_affiliation_strings":["2Sarah Cannon Research Institute at HealthONE, Denver, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Sarah Cannon Research Institute at HealthONE, Denver, CO;","institution_ids":["https://openalex.org/I4210120438"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085026927","display_name":"Veronica R. Holley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Veronica R. Holley","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021068642","display_name":"Vivianne M. Velez-Bravo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vivianne M. Velez-Bravo","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035218748","display_name":"Sapna Pradyuman Patel","orcid":"https://orcid.org/0000-0003-1339-1517","observed_orcids":["https://orcid.org/0000-0003-1339-1517"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sapna Patel","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105167216","display_name":"Ralph Zinner","orcid":"https://orcid.org/0009-0009-6812-5540","observed_orcids":["https://orcid.org/0009-0009-6812-5540"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ralph G. Zinner","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026538331","display_name":"Sarina Anne Piha-Paul","orcid":"https://orcid.org/0000-0001-9455-1660","observed_orcids":["https://orcid.org/0000-0001-9455-1660"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarina A. Piha-Paul","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044840107","display_name":"Apostolia Maria Tsimberidou","orcid":"https://orcid.org/0000-0003-2713-233X","observed_orcids":["https://orcid.org/0000-0003-2713-233X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Apostolia M. Tsimberidou","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David S. Hong","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["3UC San Diego - Moores Cancer Center, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3UC San Diego - Moores Cancer Center, La Jolla, CA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076426660","display_name":"Funda Meric\u2010Bernstam","orcid":"https://orcid.org/0000-0001-6816-6072","observed_orcids":["https://orcid.org/0000-0001-6816-6072"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Funda Meric-Bernstam","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071800834","display_name":"Filip Jank\u00fa","orcid":"https://orcid.org/0000-0002-8123-4065","observed_orcids":["https://orcid.org/0000-0002-8123-4065"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Filip Janku","raw_affiliation_strings":["1MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"75","issue":"15_Supplement","first_page":"2689","last_page":"2689"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.016200000420212746,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.996999979019165},{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":1.0},{"id":"https://openalex.org/keywords/braf-v600-mutation","display_name":"BRAF V600 mutation","score":0.925000011920929},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6880000233650208},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7720000147819519},{"id":"https://openalex.org/keywords/papillary-thyroid-carcinoma","display_name":"papillary thyroid carcinoma","score":0.9039999842643738},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.8809999823570251},{"id":"https://openalex.org/keywords/lung-adenocarcinoma","display_name":"lung adenocarcinoma","score":0.9800000190734863},{"id":"https://openalex.org/keywords/hgf-c-met-signaling","display_name":"HGF/MET signaling","score":0.7850000262260437},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.765999972820282},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8949999809265137},{"id":"https://openalex.org/keywords/plasma-cell-free-dna","display_name":"plasma cell-free DNA","score":0.6669999957084656}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.9427897930145264},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8244122266769409},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.8057155013084412},{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.7320698499679565},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5512501001358032},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5406084060668945},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.4996452331542969},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4734501540660858},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4190734624862671},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3889507055282593},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.34957221150398254},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.24791595339775085},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.15534359216690063},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.08753198385238647},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07674750685691833},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.07533815503120422},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2015-2689","doi":"https://doi.org/10.1158/1538-7445.am2015-2689","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2015-2689","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.800000011920929,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3096898172","https://openalex.org/W2762708223","https://openalex.org/W2600188869","https://openalex.org/W2898658893","https://openalex.org/W2149642154","https://openalex.org/W4282961160","https://openalex.org/W4321329198","https://openalex.org/W2998895464","https://openalex.org/W2639536160","https://openalex.org/W1968022619"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"BRAF":[2,13,38,193,220,231,293,302,392,402,426,460],"inhibitors":[3,196],"are":[4,449],"effective":[5],"in":[6,91,107,110,260,279,422,443,455,507],"advanced":[7,114,511],"melanoma":[8,299,399],"and":[9,31,41,55,130,242,263,308,320,359,373,398],"other":[10,216,230],"cancers":[11],"with":[12,80,112,150,164,191,333,415,430,445,452,459,503,509],"V600mutations;":[14],"however,":[15],"patients":[16,111,140,190,289,347,376,414,456,508],"ultimately":[17],"develop":[18],"therapeutic":[19],"resistance":[20,500],"through":[21],"activation":[22],"of":[23,71,176,182,286,344,418,425,519,524],"alternative":[24],"signaling":[25],"pathways":[26],"such":[27],"as":[28],"HGF/MET,":[29],"PDGFR":[30],"CRAF.":[32],"We":[33,59],"hypothesized":[34],"that":[35,441],"combining":[36],"the":[37,69,423,520,525],"inhibitor":[39,43,47],"vemurafenib":[40,72,146,160,442,502],"MET":[42],"crizotinib":[44,81,151,446,504],"or":[45,86,94,194,229,447,461,505],"PDGFR/CRAF":[46],"sorafenib":[48,95,165,448,506],"can":[49],"increase":[50],"efficacy":[51],"by":[52],"overcoming":[53],"intrinsic":[54],"acquired":[56],"resistance.":[57],"Methods:":[58],"designed":[60],"a":[61,316,371],"phase":[62,513],"I":[63,514],"study":[64],"(3+3":[65],"design)":[66],"to":[67,100,170,292,301,326,363,380,391,401],"determine":[68],"safety":[70],"(240-960":[73],"mg":[74,83,97,167,172],"PO":[75,84,98,102,148,153,162,168],"BID":[76,87,103,149,163,169],"q":[77,88,104],"28":[78,89,105],"days)":[79,90,106],"(250":[82],"daily":[85,99],"arm":[92,261],"A":[93,262],"(200":[96],"400mg":[101],"Arm":[108,155,280,283,341],"B":[109],"BRAF-mutant":[113,510],"cancers.":[115],"Endpoints":[116],"included":[117,252],"maximum":[118],"tolerated":[119,451],"dose":[120,122],"(MTD),":[121],"limiting":[123],"toxicities":[124,251],"(DLT),":[125],"safety,":[126],"response":[127,318],"(RECIST":[128],"1.1)":[129],"plasma":[131,419],"cell-free":[132],"DNA":[133,428],"mutation":[134],"analysis.":[135],"Results:":[136],"To":[137],"date,":[138],"29":[139],"(Arm":[141],"A,":[142,284],"n":[143,157],"=":[144,158,223,227,234,258,267,272,277],"11,":[145],"240-960mg":[147],"250mg":[152],"daily;":[154],"B,":[156,342],"18,":[159],"240-720mg":[161],"200":[166],"400/200":[171],"PO),":[173],"median":[174,180],"age":[175],"53":[177],"(33-76)":[178],"years;":[179],"number":[181],"3":[183,255,285,343,374],"(1-5)":[184],"prior":[185,192],"therapies":[186],"including":[187],"22":[188],"(76%)":[189],"MEK":[195,327,364,381,462],"were":[197],"treated.":[198],"Patients":[199],"(melanoma":[200,290,324],"17/29,":[201],"59%;":[202],"papillary":[203,387],"thyroid":[204,378,388],"cancer":[205,209,361,389],"4/29,":[206],"14%;":[207],"colorectal":[208],"3/29,":[210,217],"10%;":[211],"lung":[212,309,353],"adenocarcinoma":[213],"2/29,":[214],"7%;":[215],"10%)":[218],"had":[219],"V600E":[221],"(n":[222,226,233,257,266,271,276],"24),":[224],"V600K":[225],"3)":[228],"mutations":[232],"2).":[235],"The":[236],"MTDs":[237],"have":[238,245],"not":[239],"been":[240,246],"reached":[241],"no":[243],"DLTs":[244],"observed.":[247],"Significant":[248],"drug":[249],"related":[250],"grade":[253],"(G)":[254],"thrombocytopenia":[256],"1)":[259,278],"G3":[264,269,274],"hypertension":[265],"1),":[268,273],"headache":[270],"diarrhea":[275],"B.":[281],"In":[282,340,413],"11":[287],"(27%)":[288],"refractory":[291,300,325,362,379,390,400],"monotherapy,":[294,303],"-40%":[295],"for":[296,305,312,330,350,356,367,384,395,405,528],"7.9":[297],"months;":[298,352,386],"-36%":[304],"6.0+":[306],"months":[307,358,397],"adenocarcinoma,":[310,354],"-50%":[311,366],"13.9":[313],"months)":[314,332,369,407],"attained":[315,370,408],"partial":[317],"(PR)":[319],"1":[321],"(9%)":[322],"patient":[323],"inhibitor,":[328,365,382,393],"+3%":[329],"12.5":[331],"stable":[334],"disease":[335],"(SD)":[336],">":[337,410],"6":[338,411],"months.":[339,412],"18":[345],"(17%)":[346,375],"(melanoma,":[348],"-46%":[349],"7.6":[351],"-61%":[355],"7.3":[357],"ovarian":[360],"18.7":[368],"PR":[372],"(papillary":[377],"-10%":[383],"28.4":[385],"-6%":[394],"7.3+":[396],"monotherapy":[403],"-8%":[404],"7.5":[406],"SD":[409],"longitudinal":[416],"assessment":[417],"cfDNA":[420],"changes":[421],"amount":[424],"mutant":[427],"corresponded":[429],"clinical":[431],"course":[432],"(data":[433],"will":[434],"be":[435],"presented).":[436],"Conclusions:":[437],"Preliminary":[438],"data":[439],"suggest":[440],"combination":[444],"well":[450],"encouraging":[453],"activity":[454],"previously":[457],"treated":[458],"inhibitors.":[463],"Citation":[464],"Format:":[465],"Shumei":[466],"Kato,":[467],"Aung":[468],"Naing,":[469],"Gerald":[470],"Falchook,":[471],"Veronica":[472],"R.":[473],"Holley,":[474],"Vivianne":[475],"M.":[476,487],"Velez-Bravo,":[477],"Sapna":[478],"Patel,":[479],"Ralph":[480],"G.":[481],"Zinner,":[482],"Sarina":[483],"A.":[484],"Piha-Paul,":[485],"Apostolia":[486],"Tsimberidou,":[488],"David":[489],"S.":[490],"Hong,":[491],"Razelle":[492],"Kurzrock,":[493],"Funda":[494],"Meric-Bernstam,":[495],"Filip":[496],"Janku.":[497],"Overcoming":[498],"BRAF/MEK":[499],"using":[501],"cancers:":[512],"study.":[515],"[abstract].":[516],"In:":[517],"Proceedings":[518],"106th":[521],"Annual":[522],"Meeting":[523],"American":[526],"Association":[527],"Cancer":[529,539],"Research;":[530],"2015":[531],"Apr":[532],"18-22;":[533],"Philadelphia,":[534],"PA.":[535],"Philadelphia":[536],"(PA):":[537],"AACR;":[538],"Res":[540],"2015;75(15":[541],"Suppl):Abstract":[542],"nr":[543],"2689.":[544],"doi:10.1158/1538-7445.AM2015-2689":[545]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-07-22T00:00:00"}